Development of CDK4/6 Inhibitors in Gastrointestinal Cancers: Biomarkers to Move Forward
Targeting the cell cycle has become a focus of cancer research bearing impressive results with the introduction of CDK4/6 inhibitors in the treatment of ER-positive/HER2-negative breast cancers. However, no definitive benefit in other cancers has been observed. In gastrointestinal cancers, despite p...
Saved in:
| Main Author: | Ioannis A. Voutsadakis |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Current Issues in Molecular Biology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1467-3045/47/6/454 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunities
by: Mashael Algethami, et al.
Published: (2025-08-01) -
A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer
by: Jialin Zhang, et al.
Published: (2025-03-01) -
Factors Affecting the Survival of Metastatic Breast Cancer Patients Treated with CDK 4/6 Inhibitors
by: Zehra Sucuoğlu İşleyen, et al.
Published: (2025-07-01) -
A rational approach to dose reduction of CDK4/6 inhibitors in the treatment of patients with advanced breast cancer: A narrative Review
by: I. N. Dyakov, et al.
Published: (2025-07-01) -
CDK4/6 inhibitor PD-0332991 suppresses hepatocarcinogenesis by inducing senescence of hepatic tumor-initiating cells
by: Miaomiao Chen, et al.
Published: (2025-07-01)